Insulin glulisine Side Effects
Medically reviewed by Drugs.com. Last updated on May 15, 2022.
For the Consumer
Applies to insulin glulisine: parenteral injection
Side effects include:
Hypoglycemia, systemic hypersensitivity, injection site reaction.
For Healthcare Professionals
Applies to insulin glulisine: injectable solution, subcutaneous solution
Common (1% to 10%): Hypoglycemia, hypoglycemic seizure
Frequency not reported: Weight gain[Ref]
Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus
In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins. Permanent discontinuation occurred in 1 patient receiving insulin glulisine.[Ref]
Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine compared with insulin aspart.[Ref]
Common (1% to 10%): Infusion site reactions
Very rare (less than 0.01%): Catheter occlusions[Ref]
Rare (less than 0.1%): Lipodystrophy[Ref]
Common (1% to 10%): Urinary tract infection[Ref]
More about insulin glulisine
Related treatment guides
1. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.